In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Lexicon Pharmaceuticals, Inc.. Trade Record

NASDAQ:LXRX Lexicon Pharmaceuticals, Inc. stock gains 116.36% Exit Sep 30, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart LXRX Sep 6, 2019, priceSeries
About Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain. The company has license and collaboration agreements with Sanofi; Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Trade Information
Trade Type
Entry Date
Sep 6, 2019
Entry Price
Sell Date
Sep 30, 2019
Sell Price
Net Gain
Hold Time
16 Trading Days